Oragenics, Inc. Announces Advisory Relationship with Dr. Richard Nagelberg, DDS

TAMPA, Fla.--(EON: Enhanced Online News)--Oragenics, Inc. (OTCBB: ORNI), a nutraceutical company focused on oral care probiotics for humans and companion pets, announced today that it has entered into an agreement with dental industry leader Dr. Richard Nagelberg as part of its comprehensive strategy within the dental channel. Dr. Nagelberg will provide his consulting assistance to the Company in its on-going efforts to educate the dental community and its consumers concerning the role of probiotics in oral care.

“The extensive research which culminated in the development of EvoraPro® will drive acceptance among dental professionals. I envision implementation of EvoraPro® as a routine part of oral healthcare recommendations by the dental profession in the very near future”

Among his many accomplishments, Dr. Nagelberg has been recognized as one of the top clinicians in continuing education for the past four years from Dentistry Today. Nagelberg’s association with Oragenics is an important part of the newly launched 2012 Strategic Plan for the Company.

“The extensive research which culminated in the development of EvoraPro® will drive acceptance among dental professionals. I envision implementation of EvoraPro® as a routine part of oral healthcare recommendations by the dental profession in the very near future,” stated Dr. Richard Nagelberg, DDS.

EvoraPro®, professional strength probiotics for oral care, is a first-of-its-kind product that supports the health of teeth and periodontal tissues. These beneficial bacteria bind to teeth and go deep under the gum line, crowding out harmful bacteria. Patented EvoraPro® provides clinicians with a simple, easy and effective solution for enhancing patients’ daily at-home oral care.

“Our alliance with Dr. Nagelberg is the first step in a comprehensive plan for establishing EvoraPro® as the universally accepted probiotic agent in the dental community. This plan also includes a research based initiative for successful implementation of oral care probiotics as a routine maintenance system for enhancing oral and general health,” stated Dr. John N. Bonfiglio, Ph.D. “EvoraPro® is receiving strong support from the dental community and we look forward to expanding the awareness of probiotics as an ideal solution for supporting oral care,” added Dr. Bonfiglio.

Oragenics professional educational support will include ongoing clinical education delivered via webinars, seminars, national meetings, regional specialty meetings, detailing dental offices, expanded distributor relationships, as well as third party clinical briefs, published case studies and articles. Currently, eight clinical briefs and articles are scheduled to be published in 2012, illustrating the dental community’s continued endorsement of EvoraPro®. As a result of Oragenics association with Dr. Nagelberg, we anticipate a significant expansion in our future oral care awareness efforts.

About Dr. Nagelberg:

Dr. Richard Nagelberg has been practicing general dentistry for over 29 years. He received his DDS degree from Georgetown University in 1982. Dr. Nagelberg is a clinical consultant to OraPharma Inc. and DentoSystem, AB, a key opinion leader for Philips Sonicare, a member of the scientific advisory board for Oral DNA Labs®, and Editorial Director, Dental Education for PennWell Publishing ®. Dr. Nagelberg has a monthly column in Dental Economics ®, GP Perio-The Oral-Systemic Connection. He is co-founder of PerioFrogz.com™, an information services company. His continuing education courses may be found at www.dentaledu.tv

About Oragenics, Inc.:

Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The Company’s proprietary products Evora and ProBiora3® are currently sold in the United States and in international markets. In addition, Oragenics has an exciting pipeline of therapeutic products targeting infectious diseases.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond March 31, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

For more information visit www.oragenics.com.